Clinical trials: Food Safety
Food Allergy
Efficacy and Safety of Low-dose Sesame Oral Immunotherapy in Pediatric Patients
It is a randomized, single-center, controlled trial to evaluate the effectiveness of oral immunotherapy with low-dose sesame protein compared with standard treatment (elimination diet) in patients with sesame allergy.
- Trial name
- NCT06261554
- Testing
- Dietary Supplement: Low dose OIT
- Where
- Poland
- Volunteers
- 39 people
- Sponsor
- Medical University of Warsaw
Peanut Allergy
Study of Tolerance to Oral Peanut
Open pilot study of peanut oral immunotherapy in 22 children with peanut allergy
- Trial name
- STOP (NCT01259804)
- Testing
- Peanut oral immunotherapy
- Where
- United Kingdom
- Volunteers
- 22 people
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
Peanut Allergy
Efficacy and Safety of Several Doses of Viaskin Peanut in Adults and Children With Peanut Allergy
The objectives of this dose-finding study for the treatment of peanut allergy are: To determine the efficacy of 3 doses of Viaskin Peanut (50 mcg ,100 mcg and 250 mcg peanut protein per patch) to significantly desensitize…
- Trial name
- VIPES (NCT01675882)
- Testing
- Viaskin Peanut 50 mcg, Viaskin Peanut 100 mcg, Viaskin Peanut 250 mcg
- Where
- 24 sites in United States, Canada and 3 more
- Volunteers
- 221 people
- Sponsor
- DBV Technologies
IgE-Mediated Food Allergy, Peanut Allergy
A 52-week Study of Remibrutinib in IgE-mediated Food Allergy
The purpose of this Phase III study is to evaluate the clinical efficacy and safety of remibrutinib in participants with peanut, or cow's milk ("milk", cooked and uncooked) or hen's egg ("egg", cooked and uncooked) immunoglobulin…
- Conditions
- IgE-Mediated Food Allergy, Peanut Allergy, Cow Milk Allergy, Egg Allergy
- Trial name
- NCT07768371
- Testing
- Remibrutinib
- Where
- 18 sites in United States
- Volunteers
- 576 people
- Sponsor
- Novartis Pharmaceuticals
Food Allergy
ADP101 for Oral Immunotherapy in Food-Allergic Children and Adults
The purpose of this study is to assess the efficacy and safety of ADP101 in food allergic children and adults.
- Trial name
- NCT04856865
- Testing
- Low dose ADP101, High dose ADP101
- Where
- 15 sites in United States
- Volunteers
- 73 people
- Sponsor
- Alladapt Immunotherapeutics, Inc.
NEC, Gastroschisis
Neokare Safety and Tolerability Assessment in Neonates With GI Problems
With an increasing body of evidence to support a causal link between drinking milk that contain cow's milk protein (CMP) and the development of gastrointestinal disturbance in infants, many clinicians avoid the use of CMP…
- Conditions
- NEC, Gastroschisis, Intestinal Perforation, Atresia, Intestinal
- Trial name
- NCT05293353
- Testing
- NeoKare Breast Milk Fortifier
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Egg Allergy, Eligible for Vaccination Against Influenza
FluMist in Egg Allergic Patients
With the growing public health concerns of seasonal influenza and H1N1 in the United States, the primary means by which this can be addressed is with prevention, namely, vaccination against the influenza virus.
- Trial name
- FluEMIST (NCT01248208)
- Testing
- FluMist intranasal influenza vaccine, Intramuscular influenza injection ("flu shot")
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Walter Reed Army Medical Center
Allergy, Peanut
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Children 4-7 Years of Age
The primary purpose of this study is to assess the efficacy and safety of daily DBV712 250 micrograms (mcg) to induce desensitization to peanut in peanut-allergic children 4-7 years of age over a 12-month double-blind…
- Trial name
- VITESSE (NCT05741476)
- Testing
- DBV712
- Where
- 87 sites in United States, Australia and 7 more
- Volunteers
- 600 people
- Sponsor
- DBV Technologies
Eosinophilic Esophagitis, Milk Allergy
Milk Patch for Eosinophilic Esophagitis
This is a single-site, double-blind, placebo-controlled, randomized trial to study efficacy and safety of the Viaskin® Milk Patch for children with milk induced Eosinophilic Esophagitis (EoE).
- Trial name
- SMILEE (NCT02579876)
- Testing
- Viaskin Milk 500 mcg
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Children's Hospital of Philadelphia
Food Allergy
Improving the Safety of Oral Immunotherapy for Cow's Milk Allergy
Allergy to cow's milk is the most common food allergy affecting children. There is currently no accepted routine clinical therapy to cure milk allergy.
- Trial name
- SOCMA (NCT02216175)
- Testing
- SLIT to cow's milk, Low dose OIT, Conventional OIT to cow's milk
- Where
- 2 sites in Spain, United Kingdom
- Volunteers
- 68 people
- Sponsor
- Imperial College London
Allergies Food Milk
Dupilumab and Milk OIT for the Treatment of Cow's Milk Allergy
This is a phase 2, multicenter, randomized, double-blind, parallel group, 2 arm study in approximately 40 subjects aged 4 to 50 years, inclusive, who are allergic to cow's milk.
- Trial name
- NCT04148352
- Testing
- Dupilumab
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- Andrew J Long, PharmD
Prader-Willi Syndrome, Obesity
Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome
The purpose of this study is to evaluate efficacy and safety of ZGN-440 (beloranib) in obese adolescent and adult subjects with Prader-Willi Syndrome.
- Trial name
- bestPWS (NCT02179151)
- Testing
- ZGN-440 for Injectable Suspension
- Where
- 15 sites in United States
- Volunteers
- 108 people
- Sponsor
- Zafgen, Inc.
Peanut Allergy
High and Low Dose Oral Peanut Immunotherapy - Comparison of Efficacy and Safety
In this trial the investigators aim to assess the effectiveness and safety of oral immunotherapy with peanut protein in high and low dose (300mg versus 150mg) in children with peanuts allergy.
- Trial name
- NCT04415593
- Testing
- High dose of peanuts, Low dose of peanuts
- Where
- Poland
- Volunteers
- 44 people
- Sponsor
- Medical University of Warsaw
Systemic Allergic Reaction
The Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose
Background: Some people have allergic reactions to COVID-19 mRNA vaccines. Researchers want to learn more about these reactions to provide guidance on who can safely receive the vaccines, including a second dose in people who had…
- Trial name
- NCT04977479
- Testing
- Pfizer-BioNTech COVID-19 Vaccine (Comirnaty), Pfizer-BioNTech COVID-19 Vaccine, Bivalent
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Food Borne Diseases
Knowledge,Attitude and Practice of Food Handleres About Food Safety
The heavy burden of food borne diseases causes substantial economic losses to individual , households, health systems and entire nations.
- Trial name
- NCT04314063
- Testing
- nasal swap
- Where
- Egypt
- Volunteers
- 276 people, healthy volunteers welcome
- Sponsor
- Assiut University
HIV Infections
A Phase I Trial to Evaluate the Safety and Pharmacokinetics of 1592U89
To assess the safety of single oral doses of 1592U89 (abacavir succinate, ABC) administered to HIV-positive individuals. To determine the pharmacokinetics of 1592U89 after single oral doses.
- Trial name
- NCT00002141
- Testing
- Abacavir sulfate
- Where
- 2 sites in United States
- Volunteers
- 18 people
- Sponsor
- Burroughs Wellcome
Severe Acute Malnutrition
Modified Dosage for Severe Acute Malnutrition
Protocols for the community-based management of acute malnutrition (CMAM) have not changed significantly for more than 20 years, with relatively complex treatment protocols and persistent supply chain challenges that have limited…
- Trial name
- MODAM-SAM (NCT06061484)
- Testing
- ready-to-use therapeutic food (RUTF), Amoxicillin
- Where
- 3 sites in Ethiopia
- Volunteers
- 2,400 people
- Sponsor
- Action Against Hunger USA
Peanut Allergy
Safety and Efficacy Study of Viaskin Peanut in Peanut-allergic Young Children 1-3 Years of Age
The study aims to assess the safety and efficacy of Viaskin Peanut to induce desensitization to peanut in peanut-allergic children 1 to 3 years of age after a 12-month treatment by EPicutaneous ImmunoTherapy (EPIT).
- Trial name
- EPITOPE (NCT03211247)
- Testing
- Part A Viaskin Peanut 250 mcg, Part A Viaskin Peanut 100 mcg, Part B Viaskin Peanut 250 mcg
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 414 people
- Sponsor
- DBV Technologies
Food Allergy
Induction of Sustained Unresponsiveness to Sesame Using High- and Low-dose Sesame Oral Immunotherapy
This is an experimental, interventional study, following on from a clinical trial comparing the efficacy and safety of oral immunotherapy with low and high doses of sesame protein, in which patient desensitisation was achieved…
- Trial name
- NCT05923216
- Testing
- High dose OIT, Low dose OIT
- Where
- Poland
- Volunteers
- 40 people
- Sponsor
- Medical University of Warsaw
Food Allergy
Safety of Oral Food Challenge With Cow's Milk Proteins in Children With Food Allergy
The aim of the study is to assess the safety of an oral food challenge (OFC) with cow's milk proteins and to assess the tolerance of cow's milk proteins in children with a food allergy after introducing cow's milk into the diet.
- Trial name
- NCT04312438
- Testing
- oral food challenge with cow's milk proteins
- Where
- Poland
- Volunteers
- 1 people
- Sponsor
- Wroclaw Medical University